Rituximab by subcutaneous route
Abstract
Rituximab has become a keystone of the treatment of B-cell lymphoproliferation. The standard administration route is intravenous infusion with risks of infusion-related reactions. In order to make administration easier, increase convenience for the patient and improve cost effectiveness, a subcutaneous (sc.) form has recently been developed. Early phase clinical studies in patients with follicular lymphoma have shown that a fixed dose of 1400 mg by sc. route yielded at least non-inferior pharmacokinetics that are at least as good as those of intravenous rituximab, as measured by Ctrough levels. The safety profile was also comparable. Preliminary analyses of clinical efficacy showed at least non-inferior response rates. Although additional information is required, these results suggest that sc. rituximab may become a useful option for treating patients with B-cell non-Hodgkin's lymphoma.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Development of subcutaneous rituximab has reduced infusion time from at least 90 min with intravenous rituximab to just 6-8 min.
“Development of subcutaneous rituximab has reduced infusion time from at least 90 min with intravenous rituximab to just 6–8 min [50].”
From Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities (2018) · cites this paper as [50]
The citation lists haven’t been fetched yet
References 23 · Cited by 13
- Authors
- Solal-Celigny, P.
- Venue
- Expert Review of Hematology
- Publisher
- Informa UK Limited
- Published
- 2015-03-04
- Volume
- 8
- Issue
- 2
- Pages
- 147-153
- ISSN
- 1747-4086 (ISSN-L)
- 1747-4094
- OpenAlex
- W2074118258
- Cited by
- 13
- References
- 23
- Citations by year
- 2025: 2 · 2024: 1 · 2022: 1 · 2021: 2 · 2018: 2 · 2017: 3 · 2016: 1 · 2015: 1
- FWCI
- 1.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Expert Review of Hematology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Lymphoma Diagnosis and Treatment
- Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
- Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- Keywords
- rituximab, subcutaneous administration, B-cell lymphoproliferative disorders, follicular lymphoma, B-cell non-Hodgkin lymphoma, pharmacokinetics, non-inferiority, infusion reactions, treatment convenience
- MeSH terms
- Rituximab, Antibodies, Monoclonal, Antineoplastic Agents, Humans, Injections, Subcutaneous, Lymphoma, Follicular, Antibodies, Monoclonal, Murine-Derived
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
